All articles tagged with #genomic testing
The NHS is piloting a rapid genomic test that reduces brain tumour diagnosis times from up to eight weeks to two hours, allowing surgeons to make decisions during operations. Developed by the University of Nottingham, the test uses Oxford Nanopore technology to analyze DNA samples in a shoebox-sized machine. It is currently being tested in five specialist centres across England, with plans for wider rollout.
The NHS has launched a two-year pilot for a rapid genomic test that classifies brain tumours in two hours, reducing the standard diagnostic wait from up to eight weeks. Developed by the University of Nottingham, the technology uses Oxford Nanopore sequencing to provide surgeons with critical genetic data during operations, potentially accelerating treatment and clinical trial access for the 12,000 UK patients diagnosed annually.
A new genomic test is cutting brain tumour diagnosis times from up to eight weeks to two hours. The NHS is piloting the technology at five specialist centres in England, allowing surgeons to make critical decisions during operations. Developed by the University of Nottingham, the test uses Oxford Nanopore sequencing to analyse tumour DNA rapidly, potentially accelerating treatment and clinical trial access for the 12,000 UK patients diagnosed annually.
Researchers at UCSF have developed a metagenomic sequencing test capable of rapidly diagnosing a wide range of pathogens, including those causing neurological infections and potential pandemic threats. This test, which analyzes all nucleic acids in a sample, has been automated for respiratory samples, allowing for faster results. It has shown high accuracy in identifying infections and is expected to aid in early pandemic detection. The test has received FDA breakthrough device designation and is being commercialized by Delve Bio.
A genomic test developed at UC San Francisco, using metagenomic next-generation sequencing (mNGS), can rapidly diagnose a wide range of pathogens, including viruses, bacteria, fungi, and parasites. This test, which has been successful in identifying 86% of neurological infections, offers a significant advancement in diagnosing diseases like meningitis and encephalitis. It also holds potential for early detection of new viral pandemics. The test, now automated for faster results, has received FDA breakthrough device designation and is expected to become a critical tool in clinical diagnostics.